Fusion Pharmaceuticals Inc (FUSN)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
21.55 +0.03 (+0.14%) 06/03/24 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 21.55 unch (unch) -
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 61,925 | 44,315 | 53,567 | 90,942 | 65,624 |
| Marketable Securities | 172,153 | 127,013 | 147,897 | 131,882 | N/A |
| Receivables | 7 | 61 | 357 | N/A | N/A |
| TOTAL | $243,395 | $178,998 | $211,762 | $228,164 | $66,553 |
| Non-Current Assets | |||||
| PPE Net | 5,304 | 4,631 | 2,967 | 1,967 | 1,272 |
| Investments And Advances | 13,735 | 15,761 | 19,987 | 77,082 | 0 |
| Other Non-Current Assets | 23,402 | 19,674 | 17,555 | 3,463 | 1,575 |
| TOTAL | $42,441 | $40,066 | $40,509 | $82,512 | $2,847 |
| Total Assets | $285,836 | $219,064 | $252,271 | $310,676 | $69,400 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,860 | 2,686 | 2,195 | 3,399 | 830 |
| Accrued Expenses | 9,864 | 10,605 | 7,563 | 4,659 | 3,326 |
| TOTAL | $16,220 | $15,067 | $12,511 | $11,857 | $4,273 |
| Non-Current Liabilities | |||||
| Long Term Debt | 34,775 | 34,233 | N/A | N/A | N/A |
| Deferred Revenues | 333 | 333 | 1,538 | 1,000 | N/A |
| aiOther Non-Current Liabilities | 11,694 | 4,876 | 5,804 | 295 | 98,587 |
| TOTAL | $47,136 | $41,776 | $8,304 | $4,306 | $98,615 |
| Total Liabilities | $63,356 | $56,843 | $20,815 | $16,163 | $102,888 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 84,693 | 63,196 | 43,331 | 41,845 | N/A |
| Retained earnings | -376,759 | -281,862 | -194,250 | -113,203 | -34,774 |
| Other shareholders' equity | 237 | -469 | -115 | 44 | 0 |
| TOTAL | $222,480 | $162,221 | $231,456 | $294,513 | $-33,488 |
| Total Liabilities And Equity | $285,836 | $219,064 | $252,271 | $310,676 | $69,400 |